Binds Receptor Patents (Class 424/143.1)
  • Patent number: 11123426
    Abstract: Methods for alleviating the suppression of humoral immunity by myeloid-dependent suppressor cells (MDSCs) are provided which include the administration of a VISTA antagonist and an iNOS/NO inhibitor in a subject in need thereof, e.g., subjects with cancer or infectious disease wherein VISTA is aberrantly expressed. This combination has been discovered to elicit a synergistic or additive effect on alleviating suppression of humoral immunity by VISTA which is elicited by MDSCs.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: September 21, 2021
    Assignee: THE TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Kathy A. Green, Li Wang, Randolph J. Noelle, William R. Green
  • Patent number: 11124575
    Abstract: An Epidermal Growth Factor Receptor (EGFR, HER1, ErbB1)-binding agent has a heavy chain and a light chain, wherein the dimerization loop from EGFR's Domain II is grafted within complementarity determining region 3 (CDR3) of the heavy chain, and the binding agent is affinity matured. The graft directs the binding agent to bind EGFR at its dimerization region, to thereby inhibit EGFR dimerization and activation. In another embodiment, an EGFR-binding agent is panned out of Library F, a Fab library. The binding agents are for detecting and/or quantifying EGFR expression, for targeting EGFR-expressing cells, and for decreasing levels of EGFR in EGFR-expressing cells.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: September 21, 2021
    Assignees: University of Saskatchewan, The Governing Council of the University of Toronto
    Inventors: Sachdev Sidhu, Shane Miersch, Clarence Ronald Geyer
  • Patent number: 11118168
    Abstract: Disclosed herein are polynucleotides encoding cell tags for use in immunotherapeutic applications, and systems comprising polynucleotide cell tags for regulating the activity of a cell. The compositions, methods and systems described herein provide tools for regulating activity of genetically engineered cells in a subject.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: September 14, 2021
    Assignee: PRECIGEN, INC.
    Inventors: Rutul Shah, Peter Emtage, Ramya Yarlagadda
  • Patent number: 11098109
    Abstract: Disclosed herein are a monoclonal antibody that specifically binds to human CD133 and single-chain variable fragments thereof. Also disclosed herein is a hybridoma that produces the monoclonal antibody that specifically binds to human CD133.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: August 24, 2021
    Assignee: Regents of the University of Minnesota
    Inventor: Daniel A. Vallera
  • Patent number: 11098098
    Abstract: Provided herein are novel p62 compositions for the modulation of expression of a proinflammatory cytokines, osteogenic transcription factors, a bone resorptive factors and endogenous p62. Consequently, such p62 compositions are useful for prophylaxis and treatment of inflammatory diseases and related methods. In certain embodiments the inflammatory diseases are not cancer-related. In various embodiments, the inflammatory diseases include, but are not limited to osteoporosis, obesity, metabolic syndrome, type 2 diabetes, fat liver, inflammatory bowel disease, chronic pancreatitis, asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis (RA), osteoarthritis, multiple sclerosis (MS), psoriasis, congestive heart failure (CHF), atherosclerosis, neurodegenerative diseases (ALS, Parkinson, Alzheimer's, Huntington disease), depression, schizophrenia, gout, asbestosis and silicosis.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: August 24, 2021
    Assignee: CureLab Oncology, Inc.
    Inventors: Alexander Shneider, Franco Venanzi, Dimitrios Agas, Antonio Concetti, Maria Giovanna Sabbieti, Vladimir Gabai, Michael Sherman, Victor Shifrin
  • Patent number: 11096962
    Abstract: The present invention relates to the field of human health and more particularly concerns nanoparticles for use as a therapeutic vaccine in the context of radiotherapy in a subject suffering of a cancer, in particular of a metastatic cancer or of a liquid cancer.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: August 24, 2021
    Assignee: NANOBIOTIX
    Inventors: Julie Marill, Agnes Pottier, Laurent Levy
  • Patent number: 11066442
    Abstract: Disclosed herein are deuterated compounds, pharmaceutical compositions thereof, and methods for treating ETBR-related cancers. Also disclosed herein is a delivery system for the controlled, systemic release of at least one deuterated ETBR antagonist, optionally in conjunction with an additional anti-oncologic agent.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: July 20, 2021
    Assignee: ENB Therapeutics, Inc.
    Inventor: Sumayah Jamal
  • Patent number: 11041212
    Abstract: A method of providing a prognosis or diagnosis of prostate cancer in a subject is described. The method includes obtaining a urine or prostate sample from the subject; determining the level of expression of ABCA1 in the sample; and comparing the level of expression of ABCA1 in the sample to the level of a control sample, wherein a decreased level of ABCA1 expression compared to the control indicates the subject has prostate cancer or a more severe form of prostate cancer. Methods of treating subjects identified as having prostate cancer, and kits for carrying out the method of prognosis or diagnosis are also described.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: June 22, 2021
    Assignee: THE CLEVELAND CLINIC FOUNDATION
    Inventors: Angela H. Ting, Byron H. Lee
  • Patent number: 11034940
    Abstract: Disclosed herein are polynucleotides encoding cell tags for use in immunotherapeutic applications, and systems comprising polynucleotide cell tags for regulating the activity of a cell. The compositions, methods and systems described herein provide tools for regulating activity of genetically engineered cells in a subject.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: June 15, 2021
    Assignee: PRECIGEN, INC.
    Inventors: Rutul Shah, Peter Emtage, Ramya Yarlagadda
  • Patent number: 11028176
    Abstract: The present disclosure provides, inter alia, anti-peripheral lymph node addressin antibodies and antigen binding fragments thereof. The present disclosure also provides compositions comprising drug-containing polymeric particles that mimic lymphocyte migration in vivo and can specifically deliver immunosuppressive or immunoregulatory drugs to lymphoid tissues and sites of chronic inflammation where T-cell activation and T-cell mediated injury are occurring; such compositions comprise the antibodies or antigen-binding fragments thereof described in the disclosure. The present disclosure also comprises antibody-drug conjugates and compositions comprising the antibody-drug conjugates. Methods of preparing and using these antibodies, antigen-binding fragments thereof, and compositions thereof are also provided.
    Type: Grant
    Filed: February 12, 2020
    Date of Patent: June 8, 2021
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventor: Reza Abdi
  • Patent number: 11028182
    Abstract: Described herein are high affinity antigen binding constructs, e.g., antibodies, directed to the ECD2 domain of HER2. The antigen-binding constructs comprise at least one antigen-binding polypeptide construct that binds to ECD2 of HER2 (HER2 ECD2) with increased affinity compared to a wild-type 2C4 antibody. Such antigen-binding polypeptide constructs comprise one or more amino acid modifications in the framework region and/or CDRs compared to the amino acid sequence of a wild-type 2C4 antibody that increase affinity of the antigen-binding polypeptide construct for ECD2 by 2-fold or greater. The antigen-binding constructs can inhibit the growth of HER2-expressing breast cancer cells and gastric cancer cells. Antigen-binding constructs in biparatopic format are internalized in HER2-expressing cells.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: June 8, 2021
    Assignee: Zymeworks Inc.
    Inventors: Eric Escobar-Cabrera, Leonard G. Presta
  • Patent number: 11008620
    Abstract: Provided herein are methods for treating cancer that is resistant to treatment with an anti-ErbB therapeutic agent and which is associated with an activating MET gene mutation or a MET gene amplification. The methods involve administering to a subject a combination of an anti-ErbB therapeutic and an anti-MET therapeutic. Also provided are methods for reducing ErbB mediated signaling or PI3 kinase mediated signaling in a cancer cell.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: May 18, 2021
    Assignees: The General Hospital Corporation, Dana-Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center
    Inventors: Pasi A. Janne, Jeffrey Engelman, Lewis C. Cantley
  • Patent number: 10995152
    Abstract: Polypeptide compositions comprising a human immunoglobulin constant region with a modified IgG4 hinge region having an N-terminal deletion of 1, 2, 3, 4, 5 amino acids, relative to a native human IgG4 hinge sequence are provided. In some embodiments the hinge sequence further comprises the amino acid substitution S228P (Eu numbering). Polypeptides comprising the modified sequence optionally comprise a binding moiety specific for an epitope that is present on red blood cells; and can provide for reduced agglutination of hematopoietic cells compared to a comparable polypeptide with a native hinge region.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: May 4, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jie Liu, Irving L. Weissman, Ravindra Majeti
  • Patent number: 10982001
    Abstract: Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis and associated conditions, methods of treating systemic lupus erythematosus and associated conditions, and methods of treating multiple sclerosis.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: April 20, 2021
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Brian Wong, Emma Masteller, Justin Wong, Haishan Lin
  • Patent number: 10982000
    Abstract: The disclosure relates to novel uses and methods for preventing and/or treating heart disease, which employ a therapeutically effective amount of an ActRII receptor antagonist, e.g., an ActRII receptor binding molecule, e.g., an ActRII receptor antibody, such as the bimagrumab antibody.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: April 20, 2021
    Assignees: Novartis AG, Beth Israel Deaconess Medical Center, Inc.
    Inventors: Anthony Rosenzweig, Jason D. Roh, David J. Glass
  • Patent number: 10975159
    Abstract: Novel compounds which bind specifically to human CD160, including a light chain variable domain (VL), a chosen sequence defined by SEQ ID No: 14 or SEQ ID No: 13 and a heavy chain variable domain (VH), a sequence chosen from SEQ ID No: 11, SEQ ID No: 25, SEQ ID No: 26, SEQ ID No: 27, SEQ ID No: 28, SEQ ID No: 29 or SEQ ID No: 30, fragments thereof or derivatives thereof.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: April 13, 2021
    Assignee: ELSALYS BIOTECH
    Inventors: Alexandre Calcei, Hélène Haegel, Thierry Menguy, Caroline Rozan
  • Patent number: 10973896
    Abstract: The present invention relates to a method of treating or preventing melanoma using vaccination or immunisation, wherein said vaccination or immunisation involves the use of a photosensitizing agent, a melanoma antigen (i.e. an antigenic molecule), for example a vaccine component, and irradiation with light of a wavelength effective to activate the photosensitizing agent. The invention also relates to said photosensitizing agent and melanoma antigen for use in such a method, and to cells produced by the method.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: April 13, 2021
    Assignee: PCI Biotech AS
    Inventors: Anders Høgset, Pål Johansen
  • Patent number: 10975153
    Abstract: Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: April 13, 2021
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Julie Hambleton, Emma Masteller, James Zanghi, Robert Sikorski, Hong Xiang
  • Patent number: 10927435
    Abstract: The present invention provides compositions and methods of treating and improving the symptoms of rheumatoid arthritis using an antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R) with a DMARD.
    Type: Grant
    Filed: October 10, 2012
    Date of Patent: February 23, 2021
    Assignees: SANOFI BIOTECHNOLOGY, REGENERON PHARMACEUTICALS, INC.
    Inventors: Xiaohong Huang, Martine Jasson, Vanessa Marks, Allen Radin
  • Patent number: 10906981
    Abstract: Provided herein are compositions, kits, methods and systems related to administering a structure that crosses the blood brain barrier (BBB) along with a monosaccharide, either simultaneously or consecutively. The structure may be, for example an antibody or fusion antibody that binds to an insulin receptor.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: February 2, 2021
    Inventors: William M. Pardridge, Ruben J. Boado
  • Patent number: 10835618
    Abstract: The present invention relates to an isolated specific binding member capable of binding sialyl-di-Lewisa, and associated treatments and pharmaceutical compositions for treatment of cancer.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: November 17, 2020
    Inventors: Lindy Gillian Durrant, Mireille Vankemmelbeke, Silvana Tivadar, Tina Parsons, Richard McIntosh
  • Patent number: 10780182
    Abstract: A composition comprising at least one AAV vector formulated for central nervous system delivery is described. The composition comprises at least one expression cassette which contains sequences encoding an anti-neoplastic immunoglobulin construct for delivery to the brain operably linked to expression control sequences therefor and a pharmaceutically acceptable carrier. The anti-neoplastic immunoglobulin construct may be an immunoglobulin modified to have decreased or no measurable affinity for neonatal Fc receptor (FcRn). Also provided are methods of using these constructs in preparing pharmaceutical compositions and uses thereof in anti-neoplastic regimens, particularly for primary and/or metastatic cancers of the brain.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: September 22, 2020
    Inventors: James M. Wilson, William Thomas Rothwell, Christian Hinderer
  • Patent number: 10766962
    Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for FZD7, which preferably do not substantially interact with (bind to) other FZD family members, and methods of making said anti-FZD7 antibodies and binding fragments thereof. Another embodiment relates to antibodies and binding fragments comprising sequences of VH, VL and/or CDR polypeptides described herein. The invention also contemplates conjugates of anti-FZD7 antibodies and binding fragments. The invention further contemplates use of anti-FZD7 antibodies and binding fragments for tissue engineering. This invention also relates to a transgenic mouse expressing the epitope of anti-FZD7 antibodies and binding fragments thereof. Embodiments also pertain to use of anti-FZD7 antibodies and binding fragments (as well as the identified FZD7 epitope) for diagnosis, assessment, prevention and/or treatment of diseases and disorders associated with aberrant FZD7 expression, such as cancer.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: September 8, 2020
    Assignee: The Regents of the University of California
    Inventors: Karl Willert, Dennis Carson
  • Patent number: 10718760
    Abstract: A method of determining the specific binding of ligand reversibly binding to a binding site in a sample using displacement competitive inhibition. The method comprising incubating the ligand (unlabeled) in the absence of a labeled ligand on a first tissue specimen, incubating the ligand (unlabeled) in the presence of a labeled ligand on a second tissue specimen, the first and the second tissue specimens being adjacent sections of specimen. MALDI imaging mass spectrometry is used to subsequently visualizing bound ligand localization, using in the first and second tissue specimen, respectively.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: July 21, 2020
    Assignee: TREAT4LIFE AB
    Inventors: Gyorgy Marko-Varga, Thomas Fehniger, Yutaka Sugihara
  • Patent number: 10717782
    Abstract: Described herein are compositions, methods, and systems for modulating Notch receptor activation. Aspects of the invention relate to synthetic proteins comprising at least a Notch NRR (Negative Regulatory Region)-binding scFV fused to a transmembrane domain. Another aspect of the invention relates to drug-dependent synthetic proteins. Constructs and engineered cells comprising the synthetic proteins are additionally described herein.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: July 21, 2020
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventor: John T. Ngo
  • Patent number: 10696735
    Abstract: Combinations of different chromatography modalities with particularly refined conditions significantly reduce acid charge variants in a preparation of monoclonal antibodies. The process for reducing acid charge variants utilizes a combination of anion exchange and hydrophobic interaction chromatography, followed by cation exchange chromatography polishing, whereby the levels of acidic or basic charge species of the monoclonal antibodies may be modulated to a desired level.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: June 30, 2020
    Assignee: Outlook Therapeutics, Inc.
    Inventors: Chris Yonan, Christine Caroselli, Wiphusanee Dendamrongvit, Scott Gangloff
  • Patent number: 10689437
    Abstract: This application provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, as well as means and methods for producing them.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: June 23, 2020
    Assignee: MedImmune, LLC
    Inventors: Nancy Ulbrandt, Nicole Kallewaard-Lelay, Andy Q. Yuan, Bettina Richter
  • Patent number: 10646544
    Abstract: This invention relates to a pharmaceutical composition for treatment of a bone disease comprising, as an active ingredient, a protein comprising an extracellular cysteine-rich domain, which is from the Frizzled receptor selected from the group consisting of mammalian animal-derived Frizzled 1, Frizzled 2, and Frizzled 7 and has activity of increasing bone mass, bone density, and/or bone strength, or a mutant of such domain having sequence identity of 85% or higher to the amino acid sequence of the domain and having activity of increasing bone mass, bone density, and/or bone strength, or a vector comprising a nucleic acid encoding the protein.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: May 12, 2020
    Assignee: KYOWA KIRIN CO., LTD.
    Inventors: Makoto Kakitani, Kazuma Tomizuka
  • Patent number: 10611814
    Abstract: The present invention relates to immune cell-based anti-cancer therapeutics and methods of using the therapeutics in the treatment of cancer.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: April 7, 2020
    Assignee: GEMoaB Monoclonals GmbH
    Inventors: Michael Bachmann, Armin Ehninger
  • Patent number: 10590202
    Abstract: A bispecific antibody format, which comprises a) a Fab fragment comprising a first binding site for a first antigen; b) an scFv fragment comprising a second binding site for a second antigen; and c) a CH2 domain, wherein the Fab fragment and the scFv fragment are linked via the CH2 domain, wherein the first antigen is CD95 and the second antigen is CD20; or the first antigen is CD20 and the second antigen is CD95.
    Type: Grant
    Filed: November 19, 2013
    Date of Patent: March 17, 2020
    Assignee: BALIOPHARM AG
    Inventors: Andreas Herrmann, Ludger Grosse-Hovest
  • Patent number: 10544187
    Abstract: The present invention relates to methods and compositions for modulating T cells. The modulation includes suppressing or inducing regulatory T cells or cytotoxic T cells.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: January 28, 2020
    Assignee: Xencor, inc.
    Inventors: Seung Chu, Matthew Bernett, Dilki Wickramarachchi, John Desjarlais
  • Patent number: 10517996
    Abstract: The present invention relates to methods for recellurization of blood vessels. This method is particularly useful for producing an allogeneic vein, wherein a donor vein is decellularized and then recellularized using whole blood or bone marrow stem cells. The allogeneic veins produced by the methods disclosed herein are particularly advantageous for implantation or transplantation into patients with vascular diseases.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: December 31, 2019
    Assignee: Verigraft AB
    Inventors: Suchitra Sumitran-Holgersson, Michael Olausson
  • Patent number: 10500274
    Abstract: This invention provides a method of reducing viral load in an HIV-1-infected human subject which comprises administering to the subject an effective HIV-1 viral load reducing dose of a CCR5 receptor antagonist, such as a humanized antibody designated PRO 140 or an anti-CCR5 receptor monoclonal antibody, wherein the viral load reducing dose achieves an average maximum decrease of viral load in the subject of at least 1.83 log10 to 2.5 log10 at about ten days following administration of the CCR5 receptor antagonist and wherein the viral load reducing dose further achieves a mean viral load reduction of 1.7 log10 at about nine days following administration of the CCR5 receptor antagonist.
    Type: Grant
    Filed: September 17, 2012
    Date of Patent: December 10, 2019
    Assignee: CytoDyn Inc.
    Inventors: William C. Olson, Paul J. Maddon, Daniel C. Pevear, Robert J. Israel, Jose D. Murga
  • Patent number: 10478491
    Abstract: As described below, the present invention features methods for enhancing the efficacy of a tumor antigen in inducing an anti-cancer immune response in a subject by administering an OX40 agonist and an Indoleamine 2,3-dioxygenase (IDO) inhibitor with the tumor antigen.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: November 19, 2019
    Assignee: AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.
    Inventor: Samir Khleif
  • Patent number: 10398764
    Abstract: AnnexinA2 (ANXA2), a member of the Annexin family of calcium-dependent, phospholipid binding proteins, is one of a panel of identified antigens recognized by the post-vaccination sera of patients who demonstrated prolonged disease-free survival following multiple vaccinations. AnnexinA2 is abundantly expressed in pancreatic adenocarcinomas and cell surface/membrane AnnexinA2 increases with the progression from premalignant lesions to invasive pancreatic adenocarcinomas. The cytoplasmic to cell surface translocation of AnnexinA2 expression is critical for pancreatic cancer cell invasion. In addition, phosphorylation of AnnexinA2 at Tyrosine 23 is important for its localization to the cell surface and for the invasion of pancreatic cancer cells. Finally, loss of AnnexinA2 leads to the loss of the Epithelial-Mesenchymal Transition.
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: September 3, 2019
    Assignee: The Johns Hopkins University
    Inventors: Elizabeth Marion Jaffee, Lanqing Huang, Lei Zheng
  • Patent number: 10370449
    Abstract: The present invention provides methods for treating, preventing or ameliorating skin infections, including bacterial and viral infections. In certain embodiments, the invention provides methods to reduce skin infection in a patient with atopic dermatitis (AD). Also provided are methods for improving skin barrier function, and methods for reducing the risk of inflammation due to microbial infection in a patient in need thereof. The methods of the present invention comprise administering to a patient in need thereof a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: August 6, 2019
    Assignees: Regeneron Pharmaceuticals, Inc., Sanofi Biotechnology
    Inventors: Neil Graham, Marius Ardeleanu, Allen Radin, Jennifer D. Hamilton, Ariel Teper
  • Patent number: 10253107
    Abstract: The present invention relates to the use of endocytosis inhibitors, including clathrin-dependent endocytosis inhibitors such as inhibitors of dynamin and antibodies, for enhancing the immune response to cancer, and thereby treating cancers including cancer associated receptor positive cancers.
    Type: Grant
    Filed: October 28, 2013
    Date of Patent: April 9, 2019
    Assignee: THE UNIVERSITY OF QUEENSLAND
    Inventors: Fiona Simpson, Nicholas Andrew Saunders
  • Patent number: 10241118
    Abstract: The present invention provides methods of obtaining information relevant to monitoring and diagnosing cancer, particularly monitoring the progression or development of cancer, monitoring the response of cancer to treatment, diagnosing cancer, making a cancer prognosis, predicting the likelihood of a cancer responding to treatment and stratifying subjects having cancer. The methods involve determining the ratio of circulating CCL17 to circulating CCL22 in a sample from a subject.
    Type: Grant
    Filed: April 9, 2014
    Date of Patent: March 26, 2019
    Assignee: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Frances Balkwill, Chiara Berlato, Laura Fletcher
  • Patent number: 10231959
    Abstract: Disclosed herein are methods for counteracting age-related decrease in gene expression or treating age-related diseases, for example cancers and autoimmune diseases, caused by decreased expression levels of a gene associated with the apoptosis pathway, using a nitroxide. Further disclosed are methods for treating a human subject in need of an increased expression level of a gene associated with the apoptosis pathway using a nitroxide.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: March 19, 2019
    Inventor: Louis Habash
  • Patent number: 10221246
    Abstract: The present invention is directed to improved therapeutics against receptors within the EGFR/ErbB/HER family that more broadly interfere with multiple members of the HER family (pan-HER inhibition). More particularly, the invention is directed to the use of antibody compositions for human cancer therapy. In vitro studies have shown that the antibody compositions of the invention targeting multiple HER family receptors are superior to antibody compositions targeting only one HER family receptor.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: March 5, 2019
    Assignee: Symphogen A/S
    Inventors: Mikkel Wandahl Pedersen, Ida K. Christensen, Johan Lantto, Helle Jacobsen, Michael Kragh
  • Patent number: 10206990
    Abstract: The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of cancer, especially carcinomas, such as pancreatic carcinoma. The invention discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against pancreatic and other cancers.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: February 19, 2019
    Assignee: Immunotope, Inc.
    Inventor: Ramila Philip
  • Patent number: 10184005
    Abstract: The present invention provides novel antibodies and methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: January 22, 2019
    Assignee: MORPHOSYS AG
    Inventors: Michael Tesar, Ute Jaeger
  • Patent number: 10125195
    Abstract: The present invention relates to a stable, low viscosity antibody formulation, wherein the formulation comprises a high concentration of anti-INFAR1 antibody. In some embodiments, the invention relates in general to a stable antibody formulation comprising about 100 mg/mL to about 200 mg/mL of an antibody or fragment thereof that specifically binds human interferon alpha 1 (INFAR1); about 20 mM to about 80 mM of a lysine or a salt thereof; about 0.02% to about 0.06% of a surfactant; an uncharged excipient; and a formulation buffer. In some embodiments, the invention is directed to a container, dosage form and/or kit. In some embodiments, the invention is directed to a method of making and using the stable antibody formulation.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: November 13, 2018
    Assignee: AstraZeneca AB
    Inventors: Roberto Depaz, Natalie DeJesus, Jared Bee
  • Patent number: 10087252
    Abstract: The present invention provides compositions and methods for treating and preventing disease associated with ?v?5 integrin by blocking binding to ?v?5 integrin. In particular, antibodies specific for ?v?5 integrin are useful for preventing, treating, and reversing sepsis.
    Type: Grant
    Filed: July 26, 2010
    Date of Patent: October 2, 2018
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Dean Sheppard, George Su, Amha Atakilit
  • Patent number: 10071166
    Abstract: Disclosed are a protein conjugate with improved in vivo duration and stability and the use thereof. The protein conjugate includes a physiologically active polypeptide, a non-peptide polymer and an immunoglobulin Fc fragment. Since the three components are covalently linked, the protein conjugate has extended in vivo duration and enhanced stability for the physiologically active polypeptide. The protein conjugate maintains the in vivo activity at relatively high levels and remarkably increases the serum half-life for the physiologically active polypeptide, with less risk of inducing undesirable immune responses. Thus, the protein conjugate is useful for developing long-acting formulations of various polypeptide drugs.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: September 11, 2018
    Assignee: HANMI SCIENCE CO., LTD.
    Inventors: Young Min Kim, Dae Jin Kim, Sung Min Bae, Chang Ki Lim, Se Chang Kwon, Gwan Sun Lee
  • Patent number: 10039826
    Abstract: The current invention relates to a new pharmaceutical formulation, in particular to a pharmaceutical formulation comprising a protein, more particularly an antibody as an active ingredient.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: August 7, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Michael Joseph Edouard Boonen, Claude Peerboom
  • Patent number: 9937166
    Abstract: The embodiments described herein include methods and formulations for treating lung and brain injury. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: April 10, 2018
    Assignee: Inflammatory Response Research, Inc.
    Inventor: Bruce Chandler May
  • Patent number: 9927444
    Abstract: Methods of determining cancer progression or cancer relapse in a subject at risk for cancer progression or cancer relapse, the methods comprising: obtaining a sample from said subject; measuring the level of VEGFR1+ hematopoietic progenitor cells (HPCs) and/or VEGFR2+ endothelial progenitor cells (EPCs) in said sample; and taking additional samples and conducting additional measurements of HPCs and/or EPCs at one or more later time points. From the measurements, it can be determined whether there is a surge in the level of HPCs and/or EPCs in at least one later measurement, relative to an earlier measurement. A surge in the level of HPCs and/or EPCs indicates increased risk of progression or relapse of said subject's cancer.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: March 27, 2018
    Assignee: Cornell University
    Inventors: Linda Vahdat, Shahin Rafii, Rakhi Naik, Maureen Lane, Vivek Mittal
  • Patent number: 9920124
    Abstract: The present invention provides methods of preparing active immunoconjugates, including anti-CD22 immunoconjugates. Suitably, the methods include a fed-batch refolding process and/or column stripping process that result in an increase in yield of the immunoconjugate over other processes that do not utilize the methods.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: March 20, 2018
    Assignee: MedImmune, LLC
    Inventors: Alan Hunter, Thomas Linke, Timothy Pabst, Michaela Wendeler, Xiangyang Wang, Christopher Thompson, Guoling Xi, Andrew Fulton
  • Patent number: 9867862
    Abstract: The present invention provides compounds and methods for the treatment of an individual having or at risk of having a condition associated with alpha-1-antitrypsin by using a pharmacological chaperone. In particular, such methods are useful for the treatment and/or prevention of lung disorders associated with alpha-1-antitrypsin deficiency as well as liver disorders associated with an excess of alpha-1-antitrypsin. Suitable pharmacological chaperones include peptides and low-molecular weight compounds. The present invention also provides an assay for determining whether a test compound modulates alpha-1-antitrypsin activity.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: January 16, 2018
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Eric Richard Sjoberg, Gary Lee